Torrent Pharmaceuticals LtdNSE: TORNTPHARM
Open the Torrent Pharmaceuticals Ltd page
Follow Torrent Pharmaceuticals LtdFree account. Get a note when Torrent Pharmaceuticals Ltd files.
Q4 FY26 results analysis · May 22, 2026

Torrent Pharmaceuticals Ltd Q4 FY26 Results Analysis: Revenue Surges 42%, PAT Falls 27% on Acquisition Costs

−22.0%PAT year on year, Rs. 389.00 Cr
Cofacto ResearchPublished May 22, 20263 min readNeutral read
Quick summary

Torrent Pharmaceuticals Ltd's Q4 FY26 numbers came in mixed, with revenue of Rs. 4,197.00 Cr (+42.00% YoY) and PAT growth of -22.00% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quick Details
Results dateMay 22, 2026
QuarterQ4 FY 2025-2026
Revenue (Q4)Rs. 4,197.00 Cr (+42.00% YoY)
PAT (Q4)Rs. 389.00 Cr (-22.00% YoY)
EBITDA margin32.30% (-30 bps YoY)
Market capRs. 152,877.53 Cr
CMPRs. 4,517.05

Quarter Snapshot

Torrent Pharma reported strong 42% YoY revenue growth in Q4 FY26, but reported PAT fell 27% due to heavy acquisition-related costs from the JB Pharma purchase. The underlying Base Business continues to deliver solid 15-16% revenue growth with stable EBITDA margins of ~32.7%, though the elevated debt of Rs.14,798 crore and integration costs will weigh on reported earnings in the near term. Management's path to deleveraging (Net Debt/EBITDA of 1-1.1x by FY28) and the planned merger to eliminate minority interest are key catalysts to watch.

Key Investment Insights

Key Positives

  • Consolidated revenue grew 42% YoY to Rs.4,197 crore in Q4 FY26, and Base Business (ex-JB Pharma) grew 16% YoY to Rs.3,424 crore.
  • FY26 Base Business revenue grew 15% YoY to Rs.13,207 crore, meeting the implied guidance range.
  • Base Business EBITDA margin for FY26 was 32.7%, within 20 bps of management's stated minimum target of 32.9%.
  • Reported EBITDA grew 41% YoY to Rs.1,356 crore in Q4 FY26, with stable margin of 32.3% despite acquisition-related cost drag.
  • Operating cash flow of Rs.3,023 crore was 1.41x reported PAT and 0.66x EBITDA, indicating solid earnings quality.
  • Board recommended enabling approval for QIP/debt instruments up to Rs.5,000 crore for future growth and deleveraging.
  • Normalized PAT for Q4 FY26 was Rs.724 crore, up from reported Rs.364 crore, stripping acquisition-related one-time costs.
  • FY26 Base Business PAT grew 22% YoY to Rs.2,340 crore, showing strong underlying profitability.
  • The company has ICRA AA+ (Stable) credit rating, and management targets Net Debt/EBITDA of 1-1.1x by FY28.

Risk Factors

  • Reported PAT declined 27% YoY in Q4 FY26 due to Rs.257 crore PPA depreciation, Rs.200 crore acquisition interest, and Rs.66 crore exceptional items.
  • Total debt surged from Rs.3,026 crore to Rs.14,798 crore after the JB Pharma acquisition, with Debt/Equity rising to 1.76x from 0.40x.
  • Finance costs rose 321% YoY to Rs.236 crore, and D&A rose 153% to Rs.508 crore in Q4 FY26, both acquisition-driven.
  • Germany supply disruption continues, with Q3 revenue -6% constant currency and no recovery visible in Q4 statutory results.
  • US business run-rate of $144 million annualized is well below the $200 million target, requiring ~30% growth to meet the milestone.
  • NCI now represents 52.3% of consolidated equity (Rs.9,196 crore), meaning a large portion of JB Pharma's earnings belong to minority holders until the merger completes.
  • Interest coverage ratio fell to 4.97x in Q4 FY26 from 13.66x a year ago, reflecting higher leverage.
  • R&D spend of 4.65% of FY26 revenue was slightly below management's guidance of 5-5.5%.

Ask about this

Ask Cofacto a question about this result. Answers cite filings and company data.

Companies on this page

Related

Share on X · LinkedIn · WhatsApp

Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.